Primmune Therapeutics

Capstan Therapeutics Inc. and Engrail Therapeutics are among the latest companies to raise venture capital mega-rounds of $100m or more as the deluge of large private financings early in 2024 coinc

Arbor Biotechnologies , Acrivon Therapeutics Inc. and bit.bio are the newest members of the biopharma venture capital mega-round club after the companies announced series B rounds totaling $215m, $100

Biopharmaceutical companies raised $19.5bn in venture capital through the third quarter of 2020 and now Pitchbook and the National Venture Capital Association (NVCA) have revealed that the industry br

Three venture capital funds announced during the last two weeks of October have $989m to invest in life science companies, which should help keep the biopharmaceutical VC financing boom going beyond 2